Acceptance of the Covid-19 Vaccine to Nurses at the Lhokseumawe City Health Center
- May 5, 2023
- Posted by: rsispostadmin
- Categories: Health Sciences, IJRIAS, Nursing
International Journal of Research and Innovation in Applied Science (IJRIAS) |Volume VIII, Issue IV, April 2023|ISSN 2454-6194
Acceptance of the Covid-19 Vaccine to Nurses at the Lhokseumawe City Health Center
Mursal*, Meutia Zuhra, Fitri Yani, Novia Rizana, Nanda Fitria, Afriyanti
STIKes Muhammadiyah Lhokseumawe, Aceh, Indonesia
*Corresponding Author
DOI: https://doi.org/10.51584/IJRIAS.2023.8420
Received: 10 March 2023; Accepted: 04 April 2023; Published: 05 May 2023
Abstract: Nurses who stand at the front lines in providing health services to the community have a high risk of contracting the Covid-19 disease, so nurses become the main priority group in receiving the Covid-19 vaccine. This study aims to determine the description of the acceptance of the Covid-19 vaccine to nurses at the Lhokseumawe City Health Center. This study used a descriptive research design. The population in this study was all nurses who worked in all Public Health Centers in Lhokseumawe City, amounting to 258 people. Sampling using total sampling with a sample of 258 respondents.The data collection technique used a checklist sheet for the Covid-19 vaccination coverage for nurses at the Lhokseumawe City Health Center. The results of the univariate data analysis showed that the majority of Covid-19 vaccine receipts to nurses in Lhokseumawe City were in the complete category, namely 214 people (82.9%), while the Covid-19 vaccine receipts were in the incomplete category, namely 44 people (17.1%).The majority of nurses at the Lhokseumawe City Health Center received a complete Covid-19 vaccination. So it is recommended that respondents who have not received the complete Covid-19 vaccine can immediately take the next dose of the Covid-19 vaccine to increase their immunity from the coronavirus.
Keywords: Covid-19, Vaccine, Nurse
I. Introduction
Covid-19 prevention has entered a new stage with the availability of Covid-19 vaccines that have gone through several phases of clinical trials and can be mass-produced. Currently, as many as 8 Covid-19 vaccines have been circulating in the world, including those from Sinovac, AstraZeneca, Sinopharm, CanSino, Moderna, Pfizer-BioNTech, Janssen, and SputnikV. Indonesia is included in the category of the country with the most Covid-19 cases in Southeast Asia, participating in clinical trials of Covid-19 vaccines for several types of vaccines (Arumsari et al., 2021).
